Dermatology

Tinactin is an effective medication for athlete's foot, ringworm, and jock itch.

Apremilast is indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet disease.

Lamisil treats a variety of fungal skin infections, such as ringworm, athlete's foot, and jock itch.

Kristen Demundo, PharmD, addresses the safety and efficacy of some topical agents used as therapy options for atopic dermatitis.

Xeljanz can be used for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.

Risankizumab-rzaa treats moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Mark Becker, the CEO of Vivacare, discusses how health care professionals can counsel patients on eczema treatment and care so they can help to deter patients from googling their symptoms and developing what can be termed “medical anxiety.”

Actinic keratosis develops from years of sun exposure and usually first appears in people over 40 years of age.

Peter Lio, MD, discusses patient factors to consider before deciding on a treatment strategy for atopic dermatitis.

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDE, provides an overview of atopic dermatitis.

In a Pharmacy Times® interview, Jessica Hui, a researcher and pediatric allergist at National Jewish Health, discussed how increased hand hygiene may be harming the hands of healthcare workers.

The main factors behind the vaccine hesitancy are the potential adverse effects post-vaccination and effect on their autoimmune conditions, as well as lack of trial data, an analysis shows.

In clinical trials, the majority of patients with atopic dermatitis treated with ruxolitinib had clear or almost clear skin.

Treatment options for head live include Permethrin (Nix) and Pyrethrin (Rid) as OTC options and prescription medicines such as Ivermectin (Sklice), Spinosad (Natroba), and Malathion.

Improvements in moderate-to-severe atopic dermatitis began quickly after the first dose of dupilumab, with improved itching in 1 week and skin clearance in 2 weeks.

Dupilumab (Dupixent) was approved in 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

Psoriasis is a common, long-term chronic disease with no cure that goes through cycles, flaring for a few weeks or months, then going into remission.

Atopic dermatitis treatments include creams for itching, calcineurin inhibitors such as Protopic and Elidel, as well as biologics such as Dupixent.

The investigators concluded that a definite statement on risk or management recommendations cannot be made based on currently published data.

It is now the only 4-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe, the company said.

Trial is the first to suggest that targeting interleukin-4 and interleukin-13 can help address symptoms such as persistent itching and hives.

In the study, ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint, specifically the proportion of patients with less than or equal to 20% scalp hair loss after 6 months of treatment versus placebo.

How would you respond to these patients' concerns?

Consider key elements of acute bacterial skin and skin structure infection to help patients manage this broad range of diseases.

Patients may consult with their pharmacist regarding appropriate protection methods and treatment options available for common summer skin ailments.